Comparison of formoterol and terbutaline for treatment of asthma exacerbations in children and adolescents Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Effect of fluticasone and montelukast in school children with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 459s Year: 2007
Can response to inhaled corticosteroids in preschool children with recurrent wheezing predict asthma at age six years? Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy Year: 2012
Effects of fluticasone propionate in young children with recurrent wheeze after RSV bronchiolitis Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome Year: 2007
Clinical disposition, safety and efficacy of fluticasone propionate (FP) in pre-school children with persistent wheeze and asthma-like symptoms Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002
Effect of fluticasone and montelukast in preschool children with asthma-like symptoms Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
The effectiveness of seretide in children with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Fluticasone and montelukast in school children with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach Source: Eur Respir J 2008; 32: 1096-1110 Year: 2008
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Montelukast compared with fluticasone proprionate in children with persistent asthma Source: ISSN=ISSN 1810-6838, ISBN=, page=267 Year: 2006
Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Efficacy of fluticasone propionate in infants younger than two years with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009